+

WO2006053067A3 - Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders - Google Patents

Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders Download PDF

Info

Publication number
WO2006053067A3
WO2006053067A3 PCT/US2005/040630 US2005040630W WO2006053067A3 WO 2006053067 A3 WO2006053067 A3 WO 2006053067A3 US 2005040630 W US2005040630 W US 2005040630W WO 2006053067 A3 WO2006053067 A3 WO 2006053067A3
Authority
WO
WIPO (PCT)
Prior art keywords
amantadine
combination
effective amount
tetrabenazine
treating
Prior art date
Application number
PCT/US2005/040630
Other languages
French (fr)
Other versions
WO2006053067A2 (en
Inventor
Kathleen Clarence-Smith
Original Assignee
Prestwick Pharmaceuticals Inc
Kathleen Clarence-Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prestwick Pharmaceuticals Inc, Kathleen Clarence-Smith filed Critical Prestwick Pharmaceuticals Inc
Publication of WO2006053067A2 publication Critical patent/WO2006053067A2/en
Publication of WO2006053067A3 publication Critical patent/WO2006053067A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a method for treating a hyperkinetic movement disorder in a human patient. The method comprises administering to a patient an effective amount of amantadine, or a salt thereof, and an effective amount of a tetrabenazine compound selected from the group consisting of tetrabenazine, dihydrotetrabenazine, a salt thereof, an isomer thereof, and a combination thereof. The methods of the present invention are particularly useful in treating chorea, tardive dyskinesia, or Tourette's syndrome. The present invention further provides a pharmaceutical composition comprising an effective amount of amantadine and an effective amount of a tetrabenazine compound.
PCT/US2005/040630 2004-11-09 2005-11-08 Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders WO2006053067A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62667504P 2004-11-09 2004-11-09
US60/626,675 2004-11-09

Publications (2)

Publication Number Publication Date
WO2006053067A2 WO2006053067A2 (en) 2006-05-18
WO2006053067A3 true WO2006053067A3 (en) 2006-11-02

Family

ID=36337192

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/040630 WO2006053067A2 (en) 2004-11-09 2005-11-08 Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders

Country Status (1)

Country Link
WO (1) WO2006053067A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
CA2668689C (en) 2006-11-08 2015-12-29 Neurocrine Biosciences Inc. Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
DK3061760T3 (en) 2008-09-18 2018-02-05 Auspex Pharmaceuticals Inc DEUTERATED BENZOQUINOLIZIN DERIVATIVES AS INHIBITORS OF VESICULAR MONOAMIN TRANSPORT 2
WO2012095548A2 (en) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compounds for treating neurodegenerative disorders
JP6362601B2 (en) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Formulation pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN105873589B (en) 2013-12-03 2019-11-01 奥斯拜客斯制药有限公司 The method for manufacturing benzoquinoline compound
EP3909569A1 (en) * 2014-11-04 2021-11-17 Adamas Pharmaceuticals, Inc. Methods of administering amantadine compositions
EP3265085B1 (en) 2015-03-06 2022-07-20 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
MY191077A (en) 2017-01-27 2022-05-30 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CA3057548A1 (en) * 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
AU2018242134B2 (en) * 2017-04-01 2023-09-28 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
IL301770B2 (en) 2017-09-21 2024-06-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
SG11202003194YA (en) 2017-10-10 2020-05-28 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
CN112165942B (en) 2018-04-25 2024-04-12 新凯治疗有限公司 Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
ES2814048B2 (en) 2019-09-24 2021-08-12 Consejo Superior Investigacion COMBINED USE OF BIOTIN AND THYAMINE IN THE TREATMENT OF HUNTINGTON DISEASE
AU2020370073A1 (en) * 2019-10-22 2022-05-12 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ONDO ET AL., AM. J. PSYCHIATRY, vol. 156, no. 8, 1999, pages 1279 - 1281, XP003008956 *

Also Published As

Publication number Publication date
WO2006053067A2 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
WO2006053067A3 (en) Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
GB2410947B (en) Pharmaceutical compounds
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2010018408A3 (en) Pharmaceutical compositions with tetrabenazine
WO2004041269A3 (en) New use for pharmaceutical composition
WO2006073457A8 (en) Bioactive compounds and methods of uses thereof
WO2011019956A3 (en) Pharmaceutical compositions with tetrabenazine
WO2006116148A3 (en) (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
PL381247A1 (en) Heterocyclical condensed derivative, the medical composition containing it as well as its treatment application
WO2004006858A3 (en) Compounds, compositions, and methods employing same
MXPA03007590A (en) Compositions and methods for enhancing drug delivery across and into ocular tissues.
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2006128022A3 (en) Solid compositions and methods for treating middle-of-the night insomnia
WO2005063745A3 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
WO2005121097A3 (en) Pyrazole derivatives, compositions containing such compounds and methods of use
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
EP2332526A3 (en) Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2006130726A3 (en) Use of ladostigil for the treatment of multiple sclerosis
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2006047631A3 (en) Anti-mitotic anti-proliferative compounds
WO2006055352A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
WO2006113718A3 (en) Compositions for the treatment of neoplasms
WO2004087880A3 (en) Compounds and their use to treat diabetes and related disorders
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
WO2007044574A3 (en) Pharmaceutical compositions, methods of preparation thereof, and methods of treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase

Ref document number: 05826181

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载